These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Combination therapy with interleukin-2 and wild-type p53 expressed by adenoviral vectors potentiates tumor regression in a murine model of breast cancer. Pützer BM; Bramson JL; Addison CL; Hitt M; Siegel PM; Muller WJ; Graham FL Hum Gene Ther; 1998 Mar; 9(5):707-18. PubMed ID: 9551618 [TBL] [Abstract][Full Text] [Related]
9. In the rat liver, Adenoviral gene transfer efficiency is comparable to AAV. Montenegro-Miranda PS; Pichard V; Aubert D; Ten Bloemendaal L; Duijst S; de Waart DR; Ferry N; Bosma PJ Gene Ther; 2014 Feb; 21(2):168-74. PubMed ID: 24285217 [TBL] [Abstract][Full Text] [Related]
10. Engineering conditionally replication-competent adenoviral vectors carrying the cytosine deaminase gene increases the infectivity and therapeutic effect for breast cancer gene therapy. Liu Y; Ye T; Maynard J; Akbulut H; Deisseroth A Cancer Gene Ther; 2006 Apr; 13(4):346-56. PubMed ID: 16179927 [TBL] [Abstract][Full Text] [Related]
12. Gene transfer into hepatocytes mediated by helper virus-free HSV/AAV hybrid vectors. Fraefel C; Jacoby DR; Lage C; Hilderbrand H; Chou JY; Alt FW; Breakefield XO; Majzoub JA Mol Med; 1997 Dec; 3(12):813-25. PubMed ID: 9440115 [TBL] [Abstract][Full Text] [Related]
13. Toxicity associated with repeated administration of first-generation adenovirus vectors does not occur with a helper-dependent vector. O'Neal WK; Zhou H; Morral N; Langston C; Parks RJ; Graham FL; Kochanek S; Beaudet AL Mol Med; 2000 Mar; 6(3):179-95. PubMed ID: 10965494 [TBL] [Abstract][Full Text] [Related]
14. In vivo cancer gene therapy with a recombinant interleukin-2 adenovirus vector. Toloza EM; Hunt K; Swisher S; McBride W; Lau R; Pang S; Rhoades K; Drake T; Belldegrun A; Glaspy J; Economou JS Cancer Gene Ther; 1996; 3(1):11-7. PubMed ID: 8785705 [TBL] [Abstract][Full Text] [Related]
15. Imaging adenoviral-mediated herpes virus thymidine kinase gene transfer and expression in vivo. Tjuvajev JG; Chen SH; Joshi A; Joshi R; Guo ZS; Balatoni J; Ballon D; Koutcher J; Finn R; Woo SL; Blasberg RG Cancer Res; 1999 Oct; 59(20):5186-93. PubMed ID: 10537296 [TBL] [Abstract][Full Text] [Related]
16. Circulating anti-wild-type adeno-associated virus type 2 (AAV2) antibodies inhibit recombinant AAV2 (rAAV2)-mediated, but not rAAV5-mediated, gene transfer in the brain. Peden CS; Burger C; Muzyczka N; Mandel RJ J Virol; 2004 Jun; 78(12):6344-59. PubMed ID: 15163728 [TBL] [Abstract][Full Text] [Related]
17. Reduced toxicity, attenuated immunogenicity and efficient mediation of human p53 gene expression in vivo by an adenovirus vector with deleted E1-E3 and inactivated E4 by GAL4-TATA promoter replacement. Ji L; Bouvet M; Price RE; Roth JA; Fang B Gene Ther; 1999 Mar; 6(3):393-402. PubMed ID: 10435089 [TBL] [Abstract][Full Text] [Related]
19. Adeno-associated viral vectors penetrate human solid tumor tissue in vivo more effectively than adenoviral vectors. Enger PØ; Thorsen F; Lønning PE; Bjerkvig R; Hoover F Hum Gene Ther; 2002 Jun; 13(9):1115-25. PubMed ID: 12067444 [TBL] [Abstract][Full Text] [Related]
20. Evaluation of innate immunity and vector toxicity following inoculation of bovine, porcine or human adenoviral vectors in a mouse model. Sharma A; Bangari DS; Tandon M; Hogenesch H; Mittal SK Virus Res; 2010 Oct; 153(1):134-42. PubMed ID: 20659505 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]